Logo image
Incidence of Interstitial Lung Abnormalities: The MESA Lung Study
Journal article   Open access   Peer reviewed

Incidence of Interstitial Lung Abnormalities: The MESA Lung Study

Claire F McGroder, Spencer Hansen, Karen Hinckley Stukovsky, David Zhang, P Hrudaya Nath, Mary M Salvatore, Sushilkumar K Sonavane, Nina Terry, Justin T Stowell, Belinda M D'Souza, …
The European respiratory journal, Vol.61(6), 2201950
06/01/2023
DOI: 10.1183/13993003.01950-2022
PMCID: PMC10773573
PMID: 37202153
url
https://escholarship.org/content/qt21d4g4nq/qt21d4g4nq.pdf?t=snllweView
Open Access

Abstract

The incidence of newly developed interstitial lung abnormalities (ILA) and fibrotic ILA have not been previously reported.Trained thoracic radiologists evaluated 13 944 cardiac CT scans for the presence of ILA in 6197 Multi-Ethnic Study of Atherosclerosis longitudinal cohort study participants >45 years of age from 2000 to 2012. 5% of the scans were re-read by the same or a different observer in a blinded fashion. After exclusion of participants with ILA at baseline, incidence rates and incidence rate ratios for ILA and fibrotic ILA were calculated.The intra-reader agreement of ILA was 92.0% (Gwet AC1=0.912, ICC=0.982) and the inter-reader agreement of ILA was 83.5% (Gwet AC1=0.814; ICC=0.969). Incidence of ILA and fibrotic ILA was estimated to be 13.1 cases/1000 person-years and 3.5/1000 person-years, respectively. In multivariable analyses, age (HR 1.06 (1.05, 1.08), p <0.001; HR 1.08 (1.06, 1.11), p <0.001), high attenuation area (HAA) at baseline (HR 1.05 (1.03, 1.07), p <0.001; HR 1.06 (1.02, 1.10), p=0.002), and the promoter SNP (HR 1.73 (1.17, 2.56) p=0.01; HR 4.96 (2.68, 9.15), p <0.001) were associated with incident ILA and fibrotic ILA, respectively. Ever smoking (HR 2.31 (1.34, 3.96), p= 0.002) and an IPF polygenic risk score (HR 2.09 (1.61-2.71), p<0.001) were associated only with incident fibrotic ILA.Incident ILA and fibrotic ILA were estimated by review of cardiac imaging studies. These findings may lead to wider application of a screening tool for atherosclerosis to identify preclinical lung disease.

Details

Metrics

Logo image